Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Evolus Inc EOLS

Healthcare
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar... see more

Recent & Breaking News (NDAQ:EOLS)

Evolus to Participate in Two Upcoming Investor Conferences

GlobeNewswire November 1, 2018

Evolus Expands Leadership Team with Appointments of Key Executives

GlobeNewswire October 22, 2018

Detailed Research: Economic Perspectives on Caseys General Stores, Evolus, OptiNose, Xunlei, Molina Healthcare, and Frontline — What Drives Growth in Today's Competitive Landscape

GlobeNewswire October 22, 2018

Evolus to Release Third Quarter 2018 Financial Results on Monday, November 5, 2018

GlobeNewswire October 18, 2018

Evolus to Present at the Cantor Global Healthcare Conference

GlobeNewswire September 20, 2018

Evolus Appoints Ashwin K. Agarwal as Vice President, Finance, Investor Relations and Treasury

GlobeNewswire September 5, 2018

Evolus Receives Acceptance of FDA BLA Resubmission for DWP-450

GlobeNewswire August 29, 2018

Evolus Granted Approval of DWP-450 by Health Canada

GlobeNewswire August 17, 2018

Evolus Expands Role of Chief Medical Officer Rui Avelar, MD with Appointment as Head of R&D

GlobeNewswire August 15, 2018

Evolus, Inc. Announces Full Exercise and Closing of Underwriters’ Overallotment Option

GlobeNewswire August 15, 2018

Evolus Reports Second Quarter 2018 Financial Results

GlobeNewswire August 2, 2018

Evolus Announces Early Resubmission to the FDA of its Biologics License Application for DWP-450

GlobeNewswire August 2, 2018

Evolus to Release Second Quarter 2018 Financial Results on Thursday, August 2, 2018

GlobeNewswire July 26, 2018

Evolus, Inc. Announces Pricing of Public Offering of Common Stock

GlobeNewswire July 18, 2018

Evolus, Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire July 16, 2018

Clinical Overview of PrabotulinumtoxinA for the Investigational Treatment of Frown Lines to Be Featured During Summer Cosmetic Bootcamp 2018

GlobeNewswire June 22, 2018

Evolus Expands Management Team with Appointment of Michael Mazen Jafar as Chief Marketing Officer

GlobeNewswire June 18, 2018

Evolus to Participate in Two Upcoming Investor Conferences

GlobeNewswire June 14, 2018

Evolus to Present at the Jefferies 2018 Global Healthcare Conference

GlobeNewswire June 4, 2018

Mid-Morning Market Update: Markets Open Lower; Booz Allen Hamilton Profit Beats Estimates

Benzinga.com  May 29, 2018